[Zurück zum
Forschungsbericht]

"Concerted Safety and Efficiency Evaluation of Retroviral Transgenesis for Gene Therapy of Inherited Diseases (Consert)"

Projektbeschreibung:
CONSERT will develop and evaluate methods for genetic stem cell modification with wide implications for many other disorders including viral infection and cancer. A central theme of the project is an unbiased safety and efficiency evaluation of the key technology used in the genetic modifications of replicating somatic cells: retroviral vector-mediated transgenesis. This is only possible through concerted multi-center studies. Lenti-, spuma- and gamma-retroviral vectors will be tailor-made for target disorders and tested for potency and safety in preclinical disease models. Designed with a translational aim, basic studies in stem cell biologyand selectable marker technology will complement this research. A most important aspect of CONSERT is the molecular and clinical monitoring of currently active and successful clinical trials of genetic therapies. This will create a paradigmatic data-mining activity to obtain insights into crucial issues of clonal kinetics of gene-modified cells in vivo. Molecular studies in precise cell systems and animal models will provide the mechanistic understanding of transgene-host interactions. This project will generate the basis for technology development and promote patient safety. Translational dissemination of know-how from academia to industry will create a network of cell processing manufacturers with large economic potential, and prepare future clinical studies with improved predictability. Supervised by a proactive ethical project, CONSERT will stimulate a competitive and complementary evolution of biomedical academia, clinics, innovative health service providers, and associated training opportunities.

Weitere Informationen: http://www.mol-med.uni-freiburg.de
Ansprechpartner: Annette Deichmann
Tel: 0761/203-9612
Email: christof.kalle@uniklinik-freiburg.de
Projektlaufzeit:
Projektbeginn: 01.11.2004
Projektende: 31.10.2008
Projektleitung:
Prof. Dr. Christof von Kalle
Stellvertretung: Dr. Manfred Schmidt
Albert-Ludwigs-Universität Freiburg
Institut für Molekulare Medizin und Zellforschung (IMMZ)
Zentrum für Biochemie und Molekulare Zellforschung (ZBMZ)
Stefan-Meier-Str. 17
79104 Freiburg i. Br.

Telefon: +49-761-203-9600/9601
Fax: +49-761-203-9602
Email: christoph.peters@mol-med.uni-freiburg.de
http://www.mol-med.uni-freiburg.de
Finanzierung:

  • EU Projekt, EU

Aktueller Forschungsbericht